IM1240
-
* Purple Biotech Reaches Manufacturing Milestone for Tri-Specific Antibody IM1240 (CAPTN-3 Platform) * IM1240 Tri-Specific Antibody Production Milestone Achieved by Purple Biotech * Manufacturing Success: Purple Biotech’s IM1240 (CAPTN-3 Tri-Specific Antibody) * Purple Biotech Advances IM1240 Manufacturing, a CAPTN-3 Tri-Specific Antibody * CAPTN-3 Antibody IM1240: Purple Biotech Celebrates Production Milestone
Purple Biotech (PPBT) has achieved a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3, and NKG2A. The company reports a commercially viable yield and high-purity process, validating the CAPTN-3 platform’s scalability. IM1240 incorporates a cleavable cap to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. An Investigational New Drug (IND) submission is planned for 2026, advancing IM1240 towards first-in-human trials.
